Changing concepts in multiple myeloma: from conventional chemotherapy to high-dose treatment

The treatment of Multiple Myeloma (MM), a malignant plasma cell disorder has changed considerably over the past decade. It has been convincingly shown that intensive treatment supported by autologous stem cell reinfusion is superior to conventional chemotherapy with alkylating agents or vincristine,...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2003, Vol.39 (1), p.9-18
Main Authors: Sonneveld, P., Segeren, C.M.
Format: Article
Language:English
Subjects:
Antineoplastic agents
Antineoplastic Agents, Alkylating - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Chemotherapy
Clinical Trials, Phase II as Topic
Combined treatments (chemotherapy of immunotherapy associated with an other treatment)
Hematopoietic Stem Cell Transplantation - methods
Humans
Medical sciences
Melphalan - administration & dosage
Multiple myeloma
Multiple Myeloma - therapy
Pharmacology. Drug treatments
Randomized Controlled Trials as Topic
Recurrence
Stem cell transplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The treatment of Multiple Myeloma (MM), a malignant plasma cell disorder has changed considerably over the past decade. It has been convincingly shown that intensive treatment supported by autologous stem cell reinfusion is superior to conventional chemotherapy with alkylating agents or vincristine, doxorubicin and dexamethasone (VAD) alone in terms of a more rapid response and a longer disease-free survival. However, cure is not achieved in the majority of patients. Several trials have therefore focussed on repeated intensive treatments in order to improve the survival of these patients. Other approaches are aimed at identifying patients on the basis of prognostic factors, who may benefit from high-dose therapy. This review discusses the recent developments in intensive therapy for multiple myeloma.
ISSN:0959-8049
1879-0852
DOI:10.1016/S0959-8049(02)00503-8